Format

Send to

Choose Destination
Ther Adv Musculoskelet Dis. 2018 Jun;10(5-6):105-115. doi: 10.1177/1759720X18775936. Epub 2018 Jun 7.

The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis.

Author information

1
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
2
Department of Endocrinology and Internal Medicine, THG, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Aarhus C, Denmark.

Abstract

The glycoprotein sclerostin inhibits activation of the canonical Wnt pathway and thereby suppresses bone formation by inhibiting the osteoblasts. Additionally, sclerostin increases bone resorption by stimulating the production of receptor activator of nuclear factor kappa-β-ligand (RANKL). Romosozumab (ROMO) is a monoclonal antibody against sclerostin. Phase III clinical trials in postmenopausal women with osteoporosis have shown that ROMO increases bone mineral density at the lumbar spine and hip and reduces the risk of vertebral and clinical fractures in comparison with placebo. In women with severe osteoporosis, ROMO reduces the risk of vertebral, nonvertebral and clinical fractures in comparison with alendronate. ROMO is the first treatment for osteoporosis with dual action, and may become a valuable tool for improving the treatment of osteoporosis. At present, the approval of ROMO by the authorities is awaiting further investigations of a potential increased risk of cardiovascular events associated with ROMO treatment.

KEYWORDS:

fracture; osteoporosis; review; romosozumab; sclerostin

Conflict of interest statement

Conflict of interest statement: Torben Harsløf received lecture fees from Amgen, Astra Zeneca, and Eli Lilly. Bente Langdahl serves on advisory boards for Amgen, Eli Lilly, and UCB and has received lecture fees from Merck, Eli Lilly, TEVA and Amgen. Anne Sophie Koldkjær Sølling has nothing to disclose.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center